178 related articles for article (PubMed ID: 22517515)
1. MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk.
Wei H; Ke HL; Lin J; Shete S; Wood CG; Hildebrandt MA
Mol Carcinog; 2014 Jan; 53(1):1-7. PubMed ID: 22517515
[TBL] [Abstract][Full Text] [Related]
2. Germline polymorphisms in the Von Hippel-Lindau and Hypoxia-inducible factor 1-alpha genes, gene-environment and gene-gene interactions and renal cell cancer.
van de Pol JAA; van den Brandt PA; van Engeland M; Godschalk RWL; van Schooten FJ; Hogervorst JGF; Schouten LJ
Sci Rep; 2020 Jan; 10(1):137. PubMed ID: 31924838
[TBL] [Abstract][Full Text] [Related]
3. The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma.
Qin C; Cao Q; Ju X; Wang M; Meng X; Zhu J; Yan F; Li P; Ding Q; Chen J; Gu M; Zhang W; Yin C; Zhang Z
Ann Oncol; 2012 Apr; 23(4):981-9. PubMed ID: 21778301
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways.
Lichner Z; Mejia-Guerrero S; Ignacak M; Krizova A; Bao TT; Girgis AH; Youssef YM; Yousef GM
Am J Pathol; 2012 Apr; 180(4):1675-87. PubMed ID: 22326755
[TBL] [Abstract][Full Text] [Related]
5. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
6. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma risk is associated with the interactions of APOE, VHL and MTHFR gene polymorphisms.
Lv C; Bai Z; Liu Z; Luo P; Zhang J
Int J Clin Exp Pathol; 2015; 8(5):5781-6. PubMed ID: 26191297
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.
Chen Y; Sun Y; Rao Q; Xu H; Li L; Chang C
Oncotarget; 2015 Oct; 6(31):31203-15. PubMed ID: 26304926
[TBL] [Abstract][Full Text] [Related]
9. The VHL-dependent regulation of microRNAs in renal cancer.
Neal CS; Michael MZ; Rawlings LH; Van der Hoek MB; Gleadle JM
BMC Med; 2010 Oct; 8():64. PubMed ID: 20964835
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer.
Grampp S; Platt JL; Lauer V; Salama R; Kranz F; Neumann VK; Wach S; Stöhr C; Hartmann A; Eckardt KU; Ratcliffe PJ; Mole DR; Schödel J
Nat Commun; 2016 Oct; 7():13183. PubMed ID: 27774982
[TBL] [Abstract][Full Text] [Related]
11. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
13. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
15. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
Zhang YT; Chen N; Zeng H; Zhou Q
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
[No Abstract] [Full Text] [Related]
16. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.
Yi Y; Mikhaylova O; Mamedova A; Bastola P; Biesiada J; Alshaikh E; Levin L; Sheridan RM; Meller J; Czyzyk-Krzeska MF
Clin Cancer Res; 2010 Nov; 16(21):5142-52. PubMed ID: 20978146
[TBL] [Abstract][Full Text] [Related]
17. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
18. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
[TBL] [Abstract][Full Text] [Related]
19. Allelic loss analysis of tumor suppressor genes regardless of heterozygosity: von Hippel-Lindau gene loss in renal cell carcinoma.
Mochida J; Esumi M; Kitajima A; Okada K
J Urol; 2008 Aug; 180(2):724-8. PubMed ID: 18554638
[TBL] [Abstract][Full Text] [Related]
20. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
